ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts William J. Gradishar, MD, FASCO, FACP; Rebecca Arend, MD, MSPH; Aaron Lisberg, MD; and Ulka Vaishampayan, MD, FASCO; discuss emerging antibody-drug conjugates and bispecific agents in lung, breast, endometrial, and prostate cancers, and how these agents may shift the therapeutic landscape in these disease.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Evaluate clinical trial data for approved and investigational antibody-drug conjugates (ADCs) and bispecific antibodies across lung, breast, endometrial, and prostate cancers
• Develop biomarker-informed treatment selection and sequencing strategies for ADCs and bispecifics, integrating patient-specific factors and available evidence

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from BioNTech.

Faculty:

William J. Gradishar, MD, FASCO, FACP

Betsy Bramsen Professor of Breast Oncology and Professor of Medicine
Chief, Division of Hematology/Oncology
Feinberg School of Medicine at Northwestern University
Chicago, IL

Disclosures: Consultant: Ambryx, AstraZeneca, Carrick, Daiichi Sankyo, Genentech-Roche, Gilead Sciences, Johnson & Johnson, Lilly, Menarini-Stemline, Merck, Novartis, Pfizer, Totus, Veracyte; Data Monitoring Committee: Alliance Foundation Trials (AFT), Genentech, IBCSG, Lilly, Pfizer/Seagen

Rebecca Arend, MD, MSPH

Associate Director of Clinical Research
O'Neal Comprehensive Cancer Center
Division of Gynecology Oncology
UAB Medicine
Birmingham, AL

Disclosures: Rebecca Arend, MD, MSPH, has no relevant financial relationships with ineligible companies.

Aaron Lisberg, MD

Assistant Professor of Clinical Medicine
University of California, Los Angeles
Los Angeles, CA

Disclosures: Advisor, Consultant, Fee for Service Recipient: AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, G1 Therapeutics, Gilead Sciences, GSK, IQVIA, Janssen Oncology, Jazz Pharmaceuticals, Leica Biosystems, Molecular Axiom, MorphoSys, Novartis, Novocure, Nuvation Bio, Oncocyte, Pfizer, Regeneron, Sanofi, Whitehawk Therapeutics; Grant/Research Funding: AstraZeneca, BioNTech, Calithera Biosciences, Daiichi Sankyo, Dracen Pharmaceuticals, Duality Biologics, eFFECTOR Therapeutics, Seagen (Pfizer), WindMIL; Ownership Interests: Boston Scientific; Spouse: Paralos Bioscience; Travel: BioNTech, Duality Biologics

Ulka Vaishampayan, MD, FASCO

Beverly Mitchell Research Professor of Oncology
Co-Leader of Translational Clinical Research Program
University of Michigan Rogel Cancer Center
Ann Arbor, MI

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Bayer, BMS, Janssen, Merck, Novartis, Pfizer; Grant/Research Funding: Merck

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including insights into new therapeutic targets for ADCs and bispecific agents, go to https://www.gotoper.com/courses/adcs-and-bispecific-antibodies-across-solid-tumors-integrating-new-targets-new-data-and-new-decisions-xqku.

Release Date

July 21, 2026

Expiration Date

July 21, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.